1 / 25

The Health Company

female. The Health Company. INVESTOR PRESENTATION Q3 2014 8/1 /14. The Female Health Company manufactures and markets the FC2 Female C ondom . FC2 is the only product currently available : Approved by the FDA and cleared by the WHO Under a women’s control Which provides dual

zeph-shields
Download Presentation

The Health Company

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. female TheHealth Company INVESTOR PRESENTATION Q3 2014 8/1/14

  2. The Female Health Company manufactures and markets the FC2 Female Condom. • FC2 is the only product currently available: • Approved by the FDA and cleared by the WHO • Under a women’s control • Which provides dual • protection against: • Unintended pregnancy • Sexually transmitted infections • (STIs), including HIV/AIDS

  3. At a Glance NASDAQ FHCO Core product FC2 Female Condom Gross margin ~54% Operating margin ~23% Total current assets $15 million no L/T debt at 6/30/14

  4. Shareholder Return • Closing stock price on June 30, 2014 - $5.51 vs. June 30, 2013 - $9.86, a decrease of 44% • The average annual total return for the eight year 2005-2013 period (since becoming profitable) was 67% Stock Prices

  5. The “Worlds” of FHC Consumer Global Public Sector HIV/AIDS Global Market $4-6 Billion Family Planning Global Condom Public Health $ 400 – 500 Million

  6. HIV/AIDS Market Overview • No. 1 cause of death globally for women age 15-44 • 80% of female cases contracted via heterosexual transmission • Male and female condoms are the only prevention products available • No near-term alternative prevention products on the horizon • In Sub-Saharan Africa, women • represent >58% of adults • with HIV/AIDS infections(1 ) • Worldwide, women living with • HIV/AIDS is 50% of the global total(1 ) (1) Source: World Health Organization

  7. FC2 Female Condom vs. Male Condom FC2 is simply an alternative to the male condom * Every $1 spent on Female Condoms represents $20 in healthcare savings per the Johns Hopkins Study published in AIDS and Behavior, 2012.

  8. FHC Brand • Quality, Reliability, Safety • Partnership in solving significant global issues • HIV/AIDS, other STIs • Poverty – Family planning • Female empowerment and rights • Environment – Population control • Delivers to all stakeholders

  9. Why FC2 Demand Will Continue To Grow • Continued Global Focus on HIV • Feminization of AIDS – leading cause of death women age 15-44 • 35 million persons living with AIDS, 2.3 million newly infected in 2012 • New Global Focus on Family Planning • Addresses poverty, climate change, human rights • Gates/DFID Summit – New Funding • Female Controlled Protection • Basic rights, education, opportunity

  10. FHC Stake Holders Society, Countries, Regulatory Bodies Customers – Procurers Government/UN Agencies Investors Partners - NGO’s, Social Marketing, Advocacy Groups Distributors Customers – Users Employees Suppliers

  11. Geographic ExpansionFC2 Now Distributed Into 144 Countries • Female Health owns certain worldwide rights to FC2 • Patents and Trademarks Yellow shading shows distribution

  12. FHC Key Goals/Strategy • Accelerate and Grow Demand for FC2 • Add sales and marketing team (Utilizing portion of training budget) • Expand existing programs • Geographic expansion • Explore the potential for consumer product • Diversification of Product Offering • Leverage unique channel, market focus or capabilities • Acquisition of another product, technology and/or business 12

  13. State-of-the-Art Manufacturing 100 million unit capacity, with ability to add up to an additional 100 million units.

  14. US Programs Highlights • FC2 Prevention Programs in Key US Cities – concentrated where HIV/AIDS most prevalent. • College Campus Program launched – raise awareness of and access to FC2 on campus. • Online Ordering Presence

  15. Global Program Highlights • Multilingual (English, Portuguese, Spanish and French) website that provides downloadable training and education is visited 1,500 times per month. • YouTube multilingual FC2 animation and instruction site has received over 10 million views. • 133 training and education sessions in 7 countries with an estimated 19,749 people participating in these sessions. • More than 30 countries asked for and received information and advice on training and education.

  16. Low Risk, Unique Business Model • Modest inventory level, production primarily against orders • Low foreign currency exchange risk, FHCO & Subs Report in $USD • Minimal credit risk, less than 1% bad debt in past five years • Low sales and marketing expense, shifting some training/education funding to sales and marketing • Strong free cash flow • $2 M unused credit facility • NOL carryforward: • UK: ~$63 M – No expiration date • US: ~$19 M – Expiring in years 2018 to 2027 • State: ~$17 M – Expiring in years 2018 to 2027

  17. FY 2013 – 2012 Results

  18. Unit Sales 100% sales of lower price, higher margin, next generation FC2 CAGR 18.7 % 54.8 19.6 FC1 & FC2 FC1 FC2

  19. Net Revenues 100% sales of lower price, higher margin, next generation FC2 $31.5 $14.8 FC1 FC1 & FC2 FC2

  20. Gross Margin 100% sales of lower price, higher margin, next generation FC2 37.0 FC2 FC1 & FC2 FC1

  21. Talented Management Team • OB Parrish - Chairman • A FHCO founder • Previous Experience • Pfizer – Executive V.P. of International Division • G.D. Searle – President of Global Pharmaceuticals • Karen King – CEO and President • Effective January 20, 2014 • Previous Experience • Royal DSM – President Biologics and BioSolutions • The Female Health Company – Executive Vice President • Baxter International • Michele Greco – CFO and Vice President • Effective January 1, 2013 • Previous Experience • Ernst & Young LLP Audit Partner • Susan Ostrowski – Executive Vice President of New Business Development -- Effective July 10, 2014 • Previous Experience • DuPont, BASF, DSM, and Cambrex • Mike Pope – Vice President of Global Operations • Previous Experience • Chartex, Franklin Medical, Warner Surgical Products

  22. Competition FC2 Cupid PATH – Women’s Condom

  23. Competition

  24. FC2 Barriers To Entry • Patents principally on design and rings: • 38 patents in 50 countries • FC2 proprietary material formulation • Worldwide product specific training and education • Country registration process • FDA approval/WHO clearance 24

  25. FHC Summary • Stable, profitable company • Partner in resolving critical societal needs • Unique cost-effective business model • Small percentage of total potential market reached to date = opportunity for growth • Experienced leadership 25

More Related